Hoechst and Rhone-Poulenc deal
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.HOECHST SHAREHOLDERS yesterday overwhelmingly backed the $22bn merger of Germany's largest drugmaker with France's Rhone-Poulenc, paving the way for the creation of the joint company before the end of the year. The vote concludes a 20-hour meeting over two days, one of the longest in German corporate history. Jurgen Dormann, chief executive (left), told shareholders that Celanese, the company formed from Hoechst's industrial- chemicals businesses scheduled to be spun off in October, would cut 1,000 jobs. Both Hoechst and Rhone-Poulenc are moving away from chemicals to focus on more profitable pharmaceuticals and agrochemicals.
The merged company will have more than $20bn in annual sales and will leapfrog AstraZeneca - the product of a $40bn merger completed earlier this year - as the biggest company in the global pharmaceuticals market.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments